GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
Status:
Not yet recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of
GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for moderate
Alzheimer's disease (AD). GV1001 has been shown to inhibit neurotoxicity, apoptosis, and the
production of reactive oxygen species induced by amyloid beta in neural stem cells by
mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In
nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models,
GV1001 has been shown to improve cognitive function and memory, as well as significantly
reduce the amount of amyloid beta and tau proteins. The multifunctional effect of GV1001
makes it a promising therapeutic option for the treatment for AD.